圣湘生物发布多款呼吸道新品 以AI推动“医疗平权”

Core Viewpoint - The company, Shengxiang Bio, aims to establish a comprehensive detection system covering "hospitals - grassroots - families" through the launch of multiple products, leveraging AI technology to achieve "medical equity" [1][5]. Product Launch and Technology - Shengxiang Bio introduced the world's first AI-based molecular POCT product, the SUREXEVO series, which features 16 independent modules for parallel testing and can detect seven pathogens in one tube using eight-color fluorescence technology, significantly reducing detection time from four hours to 13 minutes and 40 seconds [5]. - The AI-enhanced enzyme technology used in the SUREXEVO series has demonstrated 100% detection effectiveness in complex samples, validated by over 2 million clinical data instances [5]. - The company plans to expand its technology to blood sample testing and aims to lead global PCR technology [5]. Comprehensive Detection System - Shengxiang Bio released various devices to meet different scenario needs, including molecular intelligent detection lines, FASTASeq300 high-throughput gene sequencers, portable multifunctional detection analyzers, and Q-POC2.0 ultra-multiplex molecular POCT products, all contributing to the establishment of a full-scene detection system [5]. - The Q-POC2.0 product focuses on critical infection detection, providing results within 30 minutes and a detection limit as low as 250 copies/mL, which is crucial for emergency patient treatment [6]. Future Plans and Collaborations - The company announced plans to launch the SUREXSTM unattended testing platform within the year, aiming to create an integrated service capability for "offline instant testing, online diagnosis and prescription, and immediate drug delivery" [6]. - This platform will be developed in collaboration with industry partners such as Meituan and JD Health, forming a comprehensive testing service ecosystem [6]. Financial Performance and R&D Investment - Recent half-year reports indicate stable revenue growth for Shengxiang Bio, with R&D investment reaching 154 million yuan, accounting for 17.71% of revenue [7]. - The company has obtained over 100 new domestic and international registration certificates and has accumulated more than 1,700 certifications, alongside the addition of over 70 new patents and software copyrights [7].